Tumor immunity in perforin-deficient mice: A role for CD95 (Fas/APO-1)

Journal of Immunology

Volumn 164, Issue 6, 2000, Pages 3229-3235

  Rosen, Dalia ^a   Li, Jie Hui ^a   Keidar, Sergey ^b   Markon, Ilya ^b   Orda, Ruben ^b   Berke, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PERFORIN;

ANIMAL CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; IMMUNOSURVEILLANCE; LUNG CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0034653437     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.6.3229     Document Type: Article

References (36)

1. Boon, T., P. G. Coulie, and B. van den Eynde. 1997. Tumor antigen recognized by T cells. Immunol. Today 18:267.
2. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
3. Berke, G. 1995. The CTL kiss of death. Cell 81:9.
4. Berke, G. 1997. The Fas-based mechanism of lymphocytotoxicity. Hum. Immunol. 54:1.
5. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
6. Podack, E. R., H. Hengartner, and M. G. Lichtenheld. 1991. A central role of perforin in cytolysis? Annu. Rev. Immunol. 9:129.
7. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
8. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
9. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
10. Walker, P. R., P. Saas, and P. Y. Dietrich. 1997. Role of Fas ligand (CD95L) in immune escape: the tumor cell strickes back. J. Immunol. 158:4521.
11. - tumor cells. Blood 92:4248.
12. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.
13. van den Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781.
14. Mori, S., A. Jewett, K. Murakami-Mori, M. Cavalcanti, and B. Bonavida. 1997. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Canter Immunol. Immunother. 44:282.
15. Walsh, C. M., M. Matloubian, C. C. Liu, R. Ueda, C. G. Kurahara, J. L. Christensen, M. T. Huang, J. D. Young, R. Ahmed, and W. R. Clark. 1994. Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. USA 91:10854.
16. Plaksin, D., C. Gelber, M. Feldman, and L. Eisenbach. 1988. Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc. Natl. Acad. Sci. USA 85:4463.
17. 2+ independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195.
18. Walsh, C. M., A. A. Glass, V. Chiu, and W. R. Clark. 1994. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153:2506.
19. Townsend, A., C. Ohlen, J. Bastin, H. G. Ljunggren, L. Foster, and K. Karre. 1989. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340:443.
20. Berke, G., K. A. Sullivan, and D. B. Amos. 1972. Rejection of ascites tumor allografts. I. Isolation, characterization and in vitro reactivity of peritoneal lymphoid effector cells from BALB/c mice immune to EL4 leukosis. J. Exp. Med. 135:1334.
21. Berke, G., D. Rosen, and D. Ronen. 1993. Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perform and granzymes. Immunology 78:105.
22. Renno, T., A. Attinger, S. Locatelli, T. Bakker, S. Vacheron, and H. R. MacDonald. 1999. Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J. Immunol. 162:6312.
23. Oehen, S., and K. Brdscha-Riem. 1998. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161:5338.
24. Van den Broek, M. F., D. Kagi, R. M. Zinkemagel, and H. Hengartner. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25:3514.
25. Cohen, P. L., and R. A. Eisenberg. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
26. Bettinardi, A., D. Brugnoni, E. Quiros-Roldan, A. Malagoli, S. La Grutta, A. Correra, and L. D. Notarangelo. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 89:902.
27. Cascino, I., G. Papoff, R. De Maria, R. Testi, and G. Ruberti. 1996. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156:13.
28. Butler, L. M., P. J. Hewett, W. J. Butler, and P. A. Cowled. 1998. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br. J. Cancer 77:1454.
29. Moller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P. H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57:371.
30. Lebel, M., R. Bertrand, and A. M. Mes-Masson. 1996. Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Oncogene 12:1127.
31. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion. Nat. Med. 2:1361.
32. Debatin, K. M., C. K. Goldmann, R. Bamford, T. A. Waldmann, and P. H. Krammer. 1990. Monoclonal-antibody-mediated apoptosis in adult T-cell leukemia. Lancet 335:497.
33. Keane, M. M., S. A. Ettenberg, G. A. Lowrey, E. K. Russell, and S. Lipkowitz. 1996. Fas expression and function in normal and maliganant breast cell lines. Cancer Res. 56:4791.
34. Nambu, Y., S. J. Hughes, A. Rehemtulla, D. Hamstra, M. B. Orringer, and D. G. Beer. 1998. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin. Invest. 101:1102.
35. Sayers, T. J., A. D. Brooks, J. K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout. 1998. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol. 161:3957.
36. Koshiji, M., Y. Adachi, S. Sogo, S. Taketani, N. Oyaizu, S. Than, M. Inaba, S. Phawa, K. Hioki, and S. Ikehara. 1998. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-α (TNF-α) and/or interferon-γ (IFN-γ), resulting from down-modulation of Bcl-2 expression. Clin. Exp. Immunol. 111:211.